Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MNTA Maxim Group Maintains Buy On Momenta Following Phase 1/2 Trial Results Of Necuparanib http://www.smarteranalyst.com/2014/10/10/maxim-group-maintains-buy-momenta-following-phase-12-trial-results-necuparanib/
$EXAS Exact Sciences: CMS Reimbursement Likely At $502 – Significant Win, Says Roth Capital http://www.smarteranalyst.com/2014/10/10/exact-sciences-cms-reimbursement-likely-502-significant-win-says-roth-capital/
$EXAS Exact Sciences: CMS Reimbursement Likely At $502 – Significant Win, Says Roth Capital http://www.smarteranalyst.com/2014/10/10/exact-sciences-cms-reimbursement-likely-502-significant-win-says-roth-capital/
$SCMP Favorable Patent Settlement With Par – A Strong Win For Sucampo, Says Roth Capital http://www.smarteranalyst.com/2014/10/10/favorable-patent-settlement-par-strong-win-sucampo-says-roth-capital/
$IRWD Ironwood: IMS Data Points To A Likely Beat On Linzess Sales But Costs Remain A Concern, Says Cowen http://www.smarteranalyst.com/2014/10/10/ironwood-ims-data-points-likely-beat-linzess-sales-costs-remain-concern-says-cowen/
$QLTI QLT Inc. Left By Auxilium: Favorable Risk/Reward In Uncertain Market http://www.smarteranalyst.com/2014/10/10/qlt-inc-left-auxilium-favorable-riskreward-uncertain-market/
$QLTI QLT Inc. Left By Auxilium: Favorable Risk/Reward In Uncertain Market http://www.smarteranalyst.com/2014/10/10/qlt-inc-left-auxilium-favorable-riskreward-uncertain-market/
$XOMA Roth Capital Assumes Bullish Stance On Xoma; Sees 137% Upside For The Stock http://www.smarteranalyst.com/2014/10/10/roth-capital-assumes-bullish-stance-xoma-sees-137-upside-stock/
$ISIS Cowen Reiterates Outperform On Isis Pharmaceuticals Following Clinical Update http://www.smarteranalyst.com/2014/10/10/cowen-reiterates-outperform-isis-pharmaceuticals-following-clinical-update/
$ARIA Ariad: We Expect Investors To Be Relieved In Light Of PRAC Review Of Iclusig Label, Says Cowen http://www.smarteranalyst.com/2014/10/10/ariad-expect-investors-relieved-light-prac-review-iclusig-label-says-cowen/
$ARIA Ariad: We Expect Investors To Be Relieved In Light Of PRAC Review Of Iclusig Label, Says Cowen http://www.smarteranalyst.com/2014/10/10/ariad-expect-investors-relieved-light-prac-review-iclusig-label-says-cowen/
$AGN Deutsche Bank Views Allergan As A Best-In-Class Specialty Pharma Company; Initiates Buy http://www.smarteranalyst.com/2014/10/09/deutsche-bank-views-allergan-best-class-specialty-pharma-company-initiates-buy/
$URG Roth Capital Maintains Buy On UR-Energy Following Q3 Production Update http://www.smarteranalyst.com/2014/10/09/roth-capital-maintains-buy-ur-energy-following-q3-production-update/
$URG Roth Capital Maintains Buy On UR-Energy Following Q3 Production Update http://www.smarteranalyst.com/2014/10/09/roth-capital-maintains-buy-ur-energy-following-q3-production-update/
$SCTY Roth Capital Reiterates Buy On SolarCity On The Back Of Loan Offerings http://www.smarteranalyst.com/2014/10/09/roth-capital-reiterates-buy-solarcity-back-new-loans-offering/
$SCTY Roth Capital Reiterates Buy On SolarCity On The Back Of Loan Offerings http://www.smarteranalyst.com/2014/10/09/roth-capital-reiterates-buy-solarcity-back-new-loans-offering/
$PLM Roth Capital Reiterates Buy On Polymet Mining, $2.25 PT http://www.smarteranalyst.com/2014/10/09/roth-capital-reiterates-buy-polymet-mining-2-25-pt/
$LGND We Continue To Be Impressed By Ligand’s Revenue Growth, Says Roth Capital http://www.smarteranalyst.com/2014/10/09/continue-impressed-ligands-revenue-growth-says-roth-capital/
$AUMN Additional Liquidity And Share Price Decline Have Created A Value Opportunity, Says Roth Capital http://www.smarteranalyst.com/2014/10/09/golden-minerals-additional-liquidity-share-price-decline-created-value-opportunity-says-roth-capital/
$EGHT William Blair Comments On 8×8 Following CFO Transition; Reiterates Outperform http://www.smarteranalyst.com/2014/10/08/william-blair-comments-on-8x8-following-cfo-transition-reiterates-outperform/
$CAMP William Blair Maintains Outperform On Calamp On The Heels Of F2Q:15 Earnings http://www.smarteranalyst.com/2014/10/08/william-blair-maintains-outperform-on-calamp-on-the-heels-of-f2q15-earnings/
$CAMP William Blair Maintains Outperform On Calamp On The Heels Of F2Q:15 Earnings http://www.smarteranalyst.com/2014/10/08/william-blair-maintains-outperform-on-calamp-on-the-heels-of-f2q15-earnings/
$SODA SodaStream: We Remain Cautious On The Shares, Says William Blair http://www.smarteranalyst.com/2014/10/08/sodastream-we-remain-cautious-on-the-shares-says-william-blair/
$SODA SodaStream: We Remain Cautious On The Shares, Says William Blair http://www.smarteranalyst.com/2014/10/08/sodastream-we-remain-cautious-on-the-shares-says-william-blair/
$BDSI William Blair Remains Bullish On BioDelivery Following Launch Update http://www.smarteranalyst.com/2014/10/08/william-blair-remains-bullish-on-biodelivery-following-launch-update/
$BDSI William Blair Remains Bullish On BioDelivery Following Launch Update http://www.smarteranalyst.com/2014/10/08/william-blair-remains-bullish-on-biodelivery-following-launch-update/
$LGND Ligand: 3Q:14 Guidance Revision Not Likely To Rally Shares Upward, Says Cantor http://www.smarteranalyst.com/2014/10/08/ligand-3q14-guidance-revision-not-likely-to-rally-shares-upward-says-cantor/
$SODA SodaStream: Roth Capital Moves To The Sidelines; Looks For Evidence Of Improved Sales Momentum http://www.smarteranalyst.com/2014/10/08/sodastream-roth-capital-moves-to-the-sidelines-looks-for-evidence-of-improved-sales-momentum/
$SODA SodaStream: Roth Capital Moves To The Sidelines; Looks For Evidence Of Improved Sales Momentum http://www.smarteranalyst.com/2014/10/08/sodastream-roth-capital-moves-to-the-sidelines-looks-for-evidence-of-improved-sales-momentum/
$PCRX Brean Capital Maintains Buy On Pacira Following Visit In Manufacturing Site http://www.smarteranalyst.com/2014/10/08/brean-capital-maintains-buy-on-pacira-following-visit-in-manufacturing-site/
$PCRX Brean Capital Maintains Buy On Pacira Following Visit In Manufacturing Site http://www.smarteranalyst.com/2014/10/08/brean-capital-maintains-buy-on-pacira-following-visit-in-manufacturing-site/
$YUM Yum!: Balance Sheet Opportunity Keep Stock Interesting, Says Oppenheimer http://www.smarteranalyst.com/2014/10/08/yum-balance-sheet-opportunity-keep-stock-interesting-says-oppenheimer/
$YUM Yum!: Balance Sheet Opportunity Keep Stock Interesting, Says Oppenheimer http://www.smarteranalyst.com/2014/10/08/yum-balance-sheet-opportunity-keep-stock-interesting-says-oppenheimer/
$SGYP Synergy: Medical Conference Expected To Reinforce Investor Interest, Says Cantor http://www.smarteranalyst.com/2014/10/08/synergy-medical-conference-expected-to-reinforce-investor-interest-says-cantor/
$SNSS Sunesis: Vosaroxin Approval In The US And EU Is Unlikely, Says Wedbush http://www.smarteranalyst.com/2014/10/07/sunesis-vosaroxin-approval-us-eu-unlikely-says-wedbush/
$SNSS Sunesis: Vosaroxin Approval In The US And EU Is Unlikely, Says Wedbush http://www.smarteranalyst.com/2014/10/07/sunesis-vosaroxin-approval-us-eu-unlikely-says-wedbush/
$CLDX Cowen Reiterates Outperform On Celldex Following Immune Oncology Panel At Cowen’s Therapeutics Conference http://www.smarteranalyst.com/2014/10/07/cowen-reiterates-outperform-celldex-following-immune-oncology-panel-cowens-therapeutics-conference/
$CAPR Capricor Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/07/capricor-represents-undervalued-player-significant-upside-says-h-c-wainwright/
$CAPR Capricor Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/07/capricor-represents-undervalued-player-significant-upside-says-h-c-wainwright/
$TWTR Twitter: Tapped Out Or Just Getting Going? Deutsche Bank Thinks The Latter http://www.smarteranalyst.com/2014/10/07/twitter-tapped-just-getting-going-deutsche-bank-thinks-latter/